Medical Doctor Program year 2023 Reported 2019–2023 Source: CMS Open Payments, 2026 publication

Victor Savinov

Geriatric Medicine Grosse Pointe Park, MI Medical Doctor

NPI 1437300845 CMS profile 201520

954 Lakepointe St, Grosse Pointe Park, MI 48230

Open in the dashboard

General payments

$536

15 records reported · program years 2019–2023

Research payments

$0

Paid to them · None reported · program years 2019–2023

Ownership & investment interest

$0

None reported

Through program year 2023, Victor Savinov of Grosse Pointe Park, MI is reported in the CMS Open Payments database as having received $536 across 15 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 68th percentile of Geriatric Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

3 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $46 2
2022 General $164 4
2019 General $326 9

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Victor Savinov
  • Geriatric Medicine median
  • Middle half of Geriatric Medicine
  • National median

In program year 2025, general payments to Victor Savinov were reported at $0. Among 1,028 Geriatric Medicine profiles paid that year, the median was $123 and the middle half received between $35 and $408.

Show as a table
Year Victor Savinov Geriatric Medicine median Middle half National median
2019 $326 $122 $40–$435 $163
2020 $0 $98 $25–$349 $114
2021 $0 $125 $34–$441 $132
2022 $164 $124 $36–$408 $149
2023 $46 $121 $41–$383 $160
2024 $0 $134 $41–$435 $164
2025 $0 $123 $35–$408 $169

Breakdown

Who paid General payments · program years 2019–2023
  1. Indivior Inc. $395 13 payments
  2. Genzyme Corporation $113 1 payment
  3. Alkermes, Inc. $28 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2023
  1. Food and Beverage $521 13 payments
  2. Education $15 2 payments
Products named General payments · program years 2019–2023
  1. SUBLOCADE Oud $326 9 payments
  2. DUPIXENT $113 1 payment
  3. SUBLOCADE Oud $68 4 payments
  4. VIVITROL $28 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 90 drugs

Part D claims

3,786

Median for Internal Medicine: 777

Drug cost

$169,697

Median for Internal Medicine: $73,373

Branded share of claims

30%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 62 $40,823
Breo Ellipta Fluticasone/Vilanterol Brand 45 $18,931
Trulicity Dulaglutide Brand 15 $13,215
Rybelsus Semaglutide Brand 13 $12,663
Januvia Sitagliptin Phosphate Brand 11 $8,662
Tradjenta Linagliptin Brand 14 $8,519
Myrbetriq Mirabegron Brand 14 $6,904
Incruse Ellipta Umeclidinium Bromide Brand 18 $5,910
Albuterol Sulfate Hfa Albuterol Sulfate Brand 139 $5,767
Metformin Hcl Generic 107 $5,445

The 10 drugs with the highest cost, of 90 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 13 billing codes

Paid by Medicare

$97,043

Of which drugs: $1,199

Medicare patients

128

Average age 73

Services billed

1,271

81 women, 47 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Diabetes 75%
High blood pressure 75%
Ischemic heart disease 75%
COPD 75%
Arthritis 71%
Heart failure 45%
Osteoporosis 45%
Chronic kidney disease 36%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Influenza vaccine, trivalent, 0.5 ml dosage 90658 Office 47 47 $1,007
Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg J3420 Office 12 36 $34

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

15 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Geriatric Medicine in Michigan

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record